A company rich in history, yet poised for the future.
Indivior began with the goal of addressing the lack of treatment for the worldwide problem of addiction. In 1994, RB established the Buprenorphine Business Group, to which Indivior can trace its history of over 20 years. The buprenorphine Business Group focused on developing buprenorphine for the treatment of opioid dependence. Even though it was an area of business that was unproven, we believed we could make a measurable difference in the lives of patients all over the world. Through a grassroots effort, we’ve partnered with and educated governments, policy makers, payers, and heathcare professionals about diseases of addiction and the value of alternative treatment options (including office-based treatment). We’ve also worked diligently and strategically to identify and address the unmet treatment needs of patients. By creating a marketplace environment of increased acceptance, we have provided an estimated 5 million patients effective treatment options with SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII), SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII), and SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) in the US alone, always keeping our focus on the individual.
We’re proud of our history but, more than that, we’re excited about our future.
Prescribing information for Indivior products available upon request.
Indivior History Highlights.
Buprenorphine Business Group established by Reckitt Benckiser to develop buprenorphine for the treatment of opioid dependence
SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) launched in France
DATA 2000 legislation in US allows physicians to treat opioid addiction
FDA approves SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) and SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII) for treatment of opioid dependence in USA
Reckitt Benckiser Pharmaceuticals launches SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII) and SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) in USA
France SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII) approval across EU
DATA 2000 (US) cap was extended from 30 to 100 patients for physicians with at least one year's clinical experience with buprenorphine
Acquired SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) rights from Monosol RX under licence
Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in US
Discontinuation of SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) in US
Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in Australia
Discontinuation of SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII) in US
Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in Malaysia
SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) received FDA approval for an expanded indication
February 2014, the Indivior entered into an agreement with AntiOp, Inc. to co-develop a naloxone nasal spray to aid in the reversal of opioid overdose with the option to acquire all rights to the product upon receipt of regulatory and marketing approval
May 2014, Indivior entered into a global licensing agreement with XenoPort, Inc. for the development and commercialization of a clinical-stage oral product candidate called arbaclofen placarbil for the treatment of alcohol use disorder
September - Indivior PLC incorporated
December 23rd - Demerger of Reckitt Benckiser Pharmaceuticals Inc. from RB Group; listing as Indivior PLC on London Stock Exchange